title: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
abstract: The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the mandate of the World Health Organization (WHO) to support countries in the reinforcement of patient care. WHO commissioned external reviews to summarise evidence on priority questions regarding case-finding, treatment regimens for multidrug-resistant TB (MDR-TB), monitoring the response to MDR-TB treatment, and models of care. A multidisciplinary expert panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to develop recommendations. The recommendations support the wider use of rapid drug susceptibility testing for isoniazid and rifampicin or rifampicin alone using molecular techniques. Monitoring by sputum culture is important for early detection of failure during treatment. Regimens lasting ≥ 20 months and containing pyrazinamide, a fluoroquinolone, a second-line injectable drug, ethionamide (or prothionamide), and either cycloserine or p-aminosalicylic acid are recommended. The guidelines promote the early use of antiretroviral agents for TB patients with HIV on second-line drug regimens. Systems that primarily employ ambulatory models of care are recommended over others based mainly on hospitalisation. Scientific and medical associations should promote the recommendations among practitioners and public health decision makers involved in MDR-TB care. Controlled trials are needed to improve the quality of existing evidence, particularly on the optimal composition and duration of MDR-TB treatment regimens.
authors.affiliation: Stop TB Dept, World Health Organization, Geneva 27, Switzerland. falzond@who.int
authors.forename: D
authors.initials: D
authors.lastname: Falzon
authors.forename: E
authors.initials: E
authors.lastname: Jaramillo
authors.forename: H J
authors.initials: HJ
authors.lastname: Schünemann
authors.forename: M
authors.initials: M
authors.lastname: Arentz
authors.forename: M
authors.initials: M
authors.lastname: Bauer
authors.forename: J
authors.initials: J
authors.lastname: Bayona
authors.forename: L
authors.initials: L
authors.lastname: Blanc
authors.forename: J A
authors.initials: JA
authors.lastname: Caminero
authors.forename: C L
authors.initials: CL
authors.lastname: Daley
authors.forename: C
authors.initials: C
authors.lastname: Duncombe
authors.forename: C
authors.initials: C
authors.lastname: Fitzpatrick
authors.forename: A
authors.initials: A
authors.lastname: Gebhard
authors.forename: H
authors.initials: H
authors.lastname: Getahun
authors.forename: M
authors.initials: M
authors.lastname: Henkens
authors.forename: T H
authors.initials: TH
authors.lastname: Holtz
authors.forename: J
authors.initials: J
authors.lastname: Keravec
authors.forename: S
authors.initials: S
authors.lastname: Keshavjee
authors.forename: A J
authors.initials: AJ
authors.lastname: Khan
authors.forename: R
authors.initials: R
authors.lastname: Kulier
authors.forename: V
authors.initials: V
authors.lastname: Leimane
authors.forename: C
authors.initials: C
authors.lastname: Lienhardt
authors.forename: C
authors.initials: C
authors.lastname: Lu
authors.forename: A
authors.initials: A
authors.lastname: Mariandyshev
authors.forename: G B
authors.initials: GB
authors.lastname: Migliori
authors.forename: F
authors.initials: F
authors.lastname: Mirzayev
authors.forename: C D
authors.initials: CD
authors.lastname: Mitnick
authors.forename: P
authors.initials: P
authors.lastname: Nunn
authors.forename: G
authors.initials: G
authors.lastname: Nwagboniwe
authors.forename: O
authors.initials: O
authors.lastname: Oxlade
authors.forename: D
authors.initials: D
authors.lastname: Palmero
authors.forename: P
authors.initials: P
authors.lastname: Pavlinac
authors.forename: M I
authors.initials: MI
authors.lastname: Quelapio
authors.forename: M C
authors.initials: MC
authors.lastname: Raviglione
authors.forename: M L
authors.initials: ML
authors.lastname: Rich
authors.forename: S
authors.initials: S
authors.lastname: Royce
authors.forename: S
authors.initials: S
authors.lastname: Rüsch-Gerdes
authors.forename: A
authors.initials: A
authors.lastname: Salakaia
authors.forename: R
authors.initials: R
authors.lastname: Sarin
authors.forename: D
authors.initials: D
authors.lastname: Sculier
authors.forename: F
authors.initials: F
authors.lastname: Varaine
authors.forename: M
authors.initials: M
authors.lastname: Vitoria
authors.forename: J L
authors.initials: JL
authors.lastname: Walson
authors.forename: F
authors.initials: F
authors.lastname: Wares
authors.forename: K
authors.initials: K
authors.lastname: Weyer
authors.forename: R A
authors.initials: RA
authors.lastname: White
authors.forename: M
authors.initials: M
authors.lastname: Zignol
mesh_terms: D000553:Ambulatory Care; D000995:Antitubercular Agents / Q000494:pharmacology; D003140:Communicable Disease Control; D054908:Extensively Drug-Resistant Tuberculosis / Q000517:prevention & control / Q000628:therapy; D017408:Guidelines as Topic; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000378:metabolism; D011634:Public Health; D013183:Sputum; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000517:prevention & control* / Q000628:therapy*; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents